CJC 1295 (No DAC)

Overview

Physiological stimulation of the GH axis via GHRH signaling.

Mechanism of action

…and avoid implying approved medical use where it doesn’t exist.

• Modified GRF (1–29) / “No DAC” = stabilized GHRH fragment concept
• CJC 1295 with DAC = long acting albumin binding pharmaceutical research design

A careful description should separate:

Scientifically, GHRH analogues were modified to resist rapid enzymatic breakdown (including DPP 4 related N terminal cleavage issues that inactivate native fragments quickly). Separate work on albumin binding versions (CJC 1295 with DAC) demonstrated markedly prolonged GH and IGF 1 stimulation in controlled clinical settings—but that long duration is tied to the DAC concept.

CJC 1295 “No DAC” is commonly used to refer to Modified GRF (1–29)—a 29 amino acid analogue of GHRH (growth hormone releasing hormone). The “No DAC” part indicates it lacks the Drug Affinity Complex (a chemical feature used in CJC 1295 with DAC to bind albumin and greatly extend half life). In practical research terms, “No DAC” versions are discussed as shorter acting GHRH analogues intended to stimulate endogenous pulsatile GH release through the GHRH receptor on pituitary somatotroph cells.

Authenticity

To validate your product, scan the QR code on the packaging or open the verification page for this product group.